ALPHA Stock Overview
A clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pharnext S.C.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0002 |
| 52 Week High | €54.00 |
| 52 Week Low | €0.0001 |
| Beta | -313.29 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| ALPHA | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -2.7% | -0.3% |
| 1Y | -100.0% | -25.5% | -4.2% |
Return vs Industry: ALPHA underperformed the French Biotechs industry which returned -25.5% over the past year.
Return vs Market: ALPHA underperformed the French Market which returned -4.2% over the past year.
Price Volatility
| ALPHA volatility | |
|---|---|
| ALPHA Average Weekly Movement | 27.7% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALPHA's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALPHA's weekly volatility has decreased from 56% to 28% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 19 | Hugo Brugiere | pharnext.com |
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Pharnext S.C.A. Fundamentals Summary
| ALPHA fundamental statistics | |
|---|---|
| Market cap | €34.00 |
| Earnings (TTM) | -€27.52m |
| Revenue (TTM) | €171.94k |
0.0x
P/S Ratio0.0x
P/E RatioIs ALPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPHA income statement (TTM) | |
|---|---|
| Revenue | €171.94k |
| Cost of Revenue | €19.35m |
| Gross Profit | -€19.18m |
| Other Expenses | €8.34m |
| Earnings | -€27.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -158.25 |
| Gross Margin | -11,153.39% |
| Net Profit Margin | -16,004.27% |
| Debt/Equity Ratio | -81.6% |
How did ALPHA perform over the long term?
See historical performance and comparison